long intergenic non-protein coding RNA 862Genealiases: C1orf98 · SMIM16
Q-omics provides the consensus-scored LINC00862 profile across patient tissues and cancer cell-line models. LINC00862 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC00862 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, LINC00862 RNA expression shows 12,751 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, LUAD, and TGCT as cancer lineages where LINC00862 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00862 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00862 survival associations across molecular data types. LINC00862 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00862 RNA expression–survival associations across cancer types. High LINC00862 expression shows unfavorable associations in UVM, MESO, ACC, KIRC, HNSC and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC00862 RNA expression.
This table summarizes LINC00862 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00862. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00862 shows higher tumor expression in LUAD, LIHC, KIRC, COAD, HNSC and BLCA. The LUAD box plot shows higher LINC00862 RNA expression in tumor versus normal tissue (log2 FC = +0.997, t-test p < 0.001).
This table shows molecular features associated with LINC00862 in patient tissues and cancer cell lines. In patient samples, LINC00862 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
